SCHILL & SEILACHER CHEMISCHE FABRIK – Trademark Portfolio

Entity Type: 99

SCHILL & SEILACHER CHEMISCHE FABRIK holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 5 filings in this category. Currently, 1 trademark is registered. Notable registered marks include LIPSOL. The owner is based in BOEBLINGEN, WURTTEMBERG.

SCHOENAICHER FIRST

BOEBLINGEN, WURTTEMBERG , DE

5 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

STRUKTOL
STRUKTOL
Cancelled 1963
LIMANOL
LIMANOL
Cancelled 1963
OSSIPOL
OSSIPOL
Cancelled 1962
LIPSOL
LIPSOL
Registered 1962

Trademark Classifications

SCHILL & SEILACHER CHEMISCHE FABRIK's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (5 filings)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

Frequently Asked Questions

How many trademarks does SCHILL & SEILACHER CHEMISCHE FABRIK have?

SCHILL & SEILACHER CHEMISCHE FABRIK has 5 U.S. trademarks filed with the USPTO. Of these, 1 registered, 4 cancelled.

What trademark classes does SCHILL & SEILACHER CHEMISCHE FABRIK file in?

SCHILL & SEILACHER CHEMISCHE FABRIK files trademarks across 1 Nice Classification class. The most active classes are Class 1 (Chemicals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What are SCHILL & SEILACHER CHEMISCHE FABRIK's most well-known trademarks?

SCHILL & SEILACHER CHEMISCHE FABRIK's registered trademark portfolio includes well-known marks such as LIPSOL. These are among 1 currently registered trademark in the portfolio.

What is SCHILL & SEILACHER CHEMISCHE FABRIK's trademark registration success rate?

SCHILL & SEILACHER CHEMISCHE FABRIK has a 20% trademark registration rate, with 1 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.